

Human IFN-γ Alexa Fluor® 594-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 25723

Catalog Number: IC285T

100 µg

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human IFN-γ in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse IFN-γ, recombinant rat IFN-γ, or recombinant porcine IFN-γ is observed. Neutralizes the bioactivity of recombinant human IFN-γ and will not neutralize the activity of rat or mouse IFN-γ.		
Source	Monoclonal Mouse IgG _{2B} Clone # 25723		
Purification	Protein A or G purified from hybridoma culture supernatant		
Immunogen	<i>E. coli</i> -derived recombinant human IFN-γ Gln24-Gln166 Accession # AAP20098.1		
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm		
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.		
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Shee (SDS) for additional information and handling instructions.		

APPLICATIONS				
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.				
	Recommended Concentration	Sample		
Intracellular Staining by Flow Cytometry	0.25-1 µg/10 ⁶ cells	Human peripheral blood mononuclear cells treated with PMA, Ionomycin, and Monensin fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012)		

PREPARATION AND STORAGE			
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Protect from light. Do not freeze. • 12 months from date of receipt, 2 to 8 °C as supplied.		

BACKGROUND

Interferon-gamma (IFN-gamma, IFNG), also known as type II or Immune Interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine. Mature human IFN-gamma exists as a non-covalently linked homodimer of 20-25 kDa molecular weight variably glycosylated subunits. Glycosylation of IFN-gamma at sites Asn25 and Asn97 is critical for protease resistance. It shares 90% amino acid (aa) sequence identity with rhesus IFN-gamma, 59-64% with bovine, canine, equine, feline, and porcine IFN- gamma, and 37-43% with cotton rat, mouse, and rat IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction. IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells. It plays a key function in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, up-regulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects. In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation. The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.



